Cefepime- and cefixime-induced encephalopathy in a patient with normal renal function.
Capparelli
F J
FJ
Raul Carrea Institute for Neurological Research (FLENI), Medical Education and Clinical Research Center Norberto Quirno, Buenos Aires, Argentina. nwainsztein@fleni.org.ar
Diaz
M F
MF
Hlavnika
A
A
Wainsztein
N A
NA
Leiguarda
R
R
Del Castillo
M E
ME
D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000378:metabolism; D001921:Brain / Q000187:drug effects* / Q000503:physiopathology; D000077723:Cefepime; D020682:Cefixime / Q000009:adverse effects* / Q000378:metabolism; D002511:Cephalosporins / Q000009:adverse effects* / Q000378:metabolism; D003221:Confusion / Q000139:chemically induced / Q000503:physiopathology; D003244:Consciousness Disorders / Q000139:chemically induced* / Q000503:physiopathology; D003693:Delirium / Q000139:chemically induced / Q000503:physiopathology; D004823:Epididymitis / Q000188:drug therapy; D006801:Humans; D007668:Kidney / Q000187:drug effects / Q000502:physiology; D008297:Male; D008657:Metabolic Clearance Rate / Q000187:drug effects / Q000502:physiology; D020258:Neurotoxicity Syndromes / Q000209:etiology* / Q000503:physiopathology; D010397:Penicillanic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D010878:Piperacillin / Q000627:therapeutic use; D020127:Recovery of Function; D055502:Secondary Prevention; D018746:Systemic Inflammatory Response Syndrome / Q000188:drug therapy / Q000209:etiology; D000078142:Tazobactam; D014552:Urinary Tract Infections / Q000188:drug therapy; D028761:Withholding Treatment
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D000077723:Cefepime; D010397:Penicillanic Acid; D020682:Cefixime; D000078142:Tazobactam; D010878:Piperacillin